JP2009544602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544602A5 JP2009544602A5 JP2009520054A JP2009520054A JP2009544602A5 JP 2009544602 A5 JP2009544602 A5 JP 2009544602A5 JP 2009520054 A JP2009520054 A JP 2009520054A JP 2009520054 A JP2009520054 A JP 2009520054A JP 2009544602 A5 JP2009544602 A5 JP 2009544602A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- pain
- optionally
- alkoxy
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 208000002193 Pain Diseases 0.000 claims 9
- 125000002837 carbocyclic group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 239000000460 chlorine Substances 0.000 claims 7
- -1 cyano, nitro, carboxy, amino Chemical group 0.000 claims 7
- 229910052731 fluorine Inorganic materials 0.000 claims 7
- 239000011737 fluorine Substances 0.000 claims 7
- 208000030761 polycystic kidney disease Diseases 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 6
- 150000001204 N-oxides Chemical class 0.000 claims 6
- 208000006011 Stroke Diseases 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 claims 1
- CCUXEBOOTMDSAM-UHFFFAOYSA-N 4-[(2,6-dichlorobenzoyl)amino]-n-(1-methylsulfonylpiperidin-4-yl)-1h-pyrazole-5-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCC1NC(=O)C1=C(NC(=O)C=2C(=CC=CC=2Cl)Cl)C=NN1 CCUXEBOOTMDSAM-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 1
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 claims 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 208000035868 Vascular inflammations Diseases 0.000 claims 1
- 206010047095 Vascular pain Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 230000037416 cystogenesis Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83267806P | 2006-07-21 | 2006-07-21 | |
| PCT/GB2007/002753 WO2008009954A1 (en) | 2006-07-21 | 2007-07-20 | Medical use of cyclin dependent kinases inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544602A JP2009544602A (ja) | 2009-12-17 |
| JP2009544602A5 true JP2009544602A5 (https=) | 2010-09-09 |
Family
ID=38522018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520054A Withdrawn JP2009544602A (ja) | 2006-07-21 | 2007-07-20 | サイクリン依存性キナーゼ阻害剤の医学的使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20090318430A1 (https=) |
| EP (1) | EP2046327A1 (https=) |
| JP (1) | JP2009544602A (https=) |
| WO (1) | WO2008009954A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| EP2070925A1 (de) * | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel |
| EP2070916A1 (de) * | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| EP2070924A1 (de) * | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel |
| CN102123990B (zh) | 2008-06-19 | 2014-07-09 | 武田药品工业株式会社 | 杂环化合物及其用途 |
| JP2012254939A (ja) * | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| JP6161537B2 (ja) | 2010-04-07 | 2017-07-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物及び使用の方法 |
| AR088061A1 (es) | 2011-09-27 | 2014-05-07 | Hoffmann La Roche | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso |
| CN103012428A (zh) | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
| CA2897665A1 (en) * | 2013-01-11 | 2014-07-17 | Mayo Foundation For Medical Education And Research | Vitamins c and k for treating polycystic diseases |
| US20150353542A1 (en) | 2013-01-14 | 2015-12-10 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| GB201313664D0 (en) * | 2013-07-31 | 2013-09-11 | Univ Cardiff | Bcl-3 inhibitors |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| HK1246645A1 (zh) | 2015-03-27 | 2018-09-14 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| CN109803684B (zh) | 2016-08-23 | 2022-08-23 | 卫材 R&D 管理有限公司 | 用于治疗肝细胞癌的组合疗法 |
| US11083722B2 (en) | 2017-03-16 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
| CN107652284B (zh) * | 2017-09-30 | 2020-01-31 | 武汉九州钰民医药科技有限公司 | 用于治疗增殖性疾病的cdk抑制剂 |
| CN109705090B (zh) * | 2017-10-25 | 2023-06-20 | 上海君实生物医药科技股份有限公司 | 3,4-二取代的1h-吡唑化合物的酒石酸加成盐及其晶型 |
| US12187701B2 (en) * | 2018-06-25 | 2025-01-07 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| JP7660063B2 (ja) | 2018-12-28 | 2025-04-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 |
| CN111848579B (zh) * | 2019-04-26 | 2023-11-14 | 君实润佳(上海)医药科技有限公司 | 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003062246A1 (en) * | 2002-01-22 | 2003-07-31 | Warner-Lambert Company Llc | 2-thia-1,6,8-triaza-naphtalene-2,2-dioxides as cdk inhibitors |
| PL2256106T3 (pl) * | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
| ATE473967T1 (de) * | 2003-11-26 | 2010-07-15 | Pfizer Prod Inc | Aminopyrazolderivate als gsk-3-inhibitoren |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
-
2007
- 2007-07-20 WO PCT/GB2007/002753 patent/WO2008009954A1/en not_active Ceased
- 2007-07-20 US US12/374,461 patent/US20090318430A1/en not_active Abandoned
- 2007-07-20 JP JP2009520054A patent/JP2009544602A/ja not_active Withdrawn
- 2007-07-20 EP EP07766316A patent/EP2046327A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544602A5 (https=) | ||
| JP2008528469A5 (https=) | ||
| JP2020526561A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| JP2008510828A5 (https=) | ||
| JP2009536620A5 (https=) | ||
| NO20076450L (no) | Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi | |
| RU2013114852A (ru) | Оксопиперазин-азетин амиды и оксодиазепин-азетидин амиды в качестве ингибиторов моноацилглицерол липазы | |
| JP2016513696A5 (https=) | ||
| BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
| EA201171333A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| JP2009519243A5 (https=) | ||
| NO20083567L (no) | Hydantoinderivater for behandling av inflammatoriske forstyrrelser | |
| JPWO2020086739A5 (https=) | ||
| JP2010501478A5 (https=) | ||
| JP2007534702A5 (https=) | ||
| JP2017508795A5 (https=) | ||
| JP2019519586A5 (https=) | ||
| JP2021523241A5 (https=) | ||
| CR20200418A (es) | Inhibidores de orginasa y sus mètodos de uso antecedentes | |
| EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| DK2061452T3 (da) | Anvendelse af koffeinsyre og derivater deraf mod cancer | |
| NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
| JP2017519802A5 (https=) |